RGLS vs. EBS, ALIM, RIGL, MACK, VSTM, BOLT, VNDA, XOMA, LXRX, and CRVO
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Emergent BioSolutions (EBS), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Bolt Biotherapeutics (BOLT), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Emergent BioSolutions (NYSE:EBS) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
Emergent BioSolutions has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
In the previous week, Emergent BioSolutions had 2 more articles in the media than Regulus Therapeutics. MarketBeat recorded 4 mentions for Emergent BioSolutions and 2 mentions for Regulus Therapeutics. Emergent BioSolutions' average media sentiment score of 1.13 beat Regulus Therapeutics' score of 0.20 indicating that Regulus Therapeutics is being referred to more favorably in the news media.
Regulus Therapeutics has a net margin of 0.00% compared to Regulus Therapeutics' net margin of -72.11%. Regulus Therapeutics' return on equity of -37.35% beat Emergent BioSolutions' return on equity.
78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 8.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Regulus Therapeutics has lower revenue, but higher earnings than Emergent BioSolutions. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions presently has a consensus target price of $5.00, suggesting a potential upside of 160.42%. Regulus Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 199.59%. Given Emergent BioSolutions' stronger consensus rating and higher possible upside, analysts plainly believe Regulus Therapeutics is more favorable than Emergent BioSolutions.
Regulus Therapeutics received 68 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.45% of users gave Emergent BioSolutions an outperform vote while only 63.49% of users gave Regulus Therapeutics an outperform vote.
Summary
Regulus Therapeutics beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
